Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Artificial Intelligence (AI)-Driven Drug Safety And Pharmacovigilance Platforms Market Size Forecast: How Large Could The Market Become By 2030?
The artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms market size has experienced significant expansion in recent years. It is projected to climb from $2.14 billion in 2025 to $2.59 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 20.6%. The historical surge in this market can be ascribed to a global rise in adverse drug reaction reporting mandates, the increasing digitalization of clinical trial information, the broadening of pharmacovigilance regulatory structures, an uptick in pharmaceutical research initiatives, and the incorporation of electronic health records within healthcare systems.
The market for artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms is projected to experience rapid expansion over the coming years. This market is anticipated to reach a valuation of $5.39 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 20.2%. Factors driving this growth during the projection period include the integration of AI into drug safety surveillance, the broader application of real-world evidence in pharmacovigilance, increasing regulatory requirements for automated compliance reporting, the development of predictive safety analytics platforms, and the growing uptake of cloud-based drug safety monitoring systems. Key trends expected in the forecast timeframe encompass AI-powered systems for detecting adverse events, the use of natural language processing for extracting safety signals, advanced predictive pharmacovigilance analytics, real-time drug safety monitoring leveraging real-world data, and automated regulatory safety reporting systems.
Download A Free Sample Report For Comprehensive Market Insights:
Artificial Intelligence (AI)-Driven Drug Safety And Pharmacovigilance Platforms Market Expansion Supported By Key Demand Factors
The increasing number of adverse event (AE) reports is projected to boost the expansion of the artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms market moving ahead. These reports document unforeseen and detrimental responses or effects observed subsequent to the administration of a medical product or drug. The surge in AE reports stems from more stringent regulatory mandates, which obligate healthcare providers and pharmaceutical firms to disclose a broader spectrum of safety concerns with higher frequency and greater specificity. Artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms handle adverse event (AE) reports by consolidating information from clinical systems, electronic health records, and real-world origins, enabling them to identify and categorize safety signals, streamline case processing, and enhance the pace and precision of regulatory decisions. As an illustration, in February 2024, the Analysis Of Adverse Drug Reactions 2023 Report from the Department of Health Abu Dhabi, a UAE-based regulatory authority, revealed that 1,522 adverse drug reaction reports were submitted to the pharmacovigilance program from January to December 2023. This figure signifies a 235% rise when compared to the average yearly report count from prior years. Consequently, the growing quantity of adverse event (AE) reports is propelling the expansion of the artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms market.
Artificial Intelligence (AI)-Driven Drug Safety And Pharmacovigilance Platforms Market Categorization By Product Type And Application
The artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms market covered in this report is segmented –
1) By Component: Software Platforms; Services
2) By Deployment Mode: Cloud-Based; On-Premise; Hybrid
3) By Enterprise Size: Large Enterprises; Small And Medium-Sized Enterprises
4) By Application: Case Processing And Management; Signal Detection And Management; Risk Management And Reporting; Regulatory Compliance
5) By End User: Pharmaceutical Companies; Biotechnology Companies; Contract Research Organizations; Regulatory Authorities; Healthcare Providers; Academic And Research Institutes
Subsegments:
1) By Software Platforms: Adverse Event Monitoring Software Platforms; Natural Language Processing Based Pharmacovigilance Platforms; Predictive Analytics And Safety Intelligence Platforms
2) By Services: Implementation And Integration Services; Consulting And Regulatory Compliance Services; Artificial Intelligence Model Training And Validation Services; Maintenance And Support Services
Technological Advancements In AI-Enabled Pharmacovigilance Systems Transforming End-To-End Drug Safety Workflows
Major companies operating in the artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms market are focusing on developing innovative treatments, such as agentic AI-driven pharmacovigilance platforms, to enhance automated adverse event detection, regulatory compliance, and efficiency in drug safety monitoring by reducing manual case-processing workloads and improving signal detection accuracy. Agentic AI pharmacovigilance platforms are advanced software systems that use domain-trained machine learning models, natural language processing, and workflow orchestration to independently perform and coordinate safety tasks such as case intake, literature surveillance, signal detection, and aggregate reporting. For instance, in May 2026, RxLogix Systems Inc., a US-based pharmacovigilance solutions company, launched the upgraded PVOne.AI platform, an AI-enabled pharmacovigilance system that integrates agentic AI capabilities to automate and orchestrate end-to-end drug safety workflows. The platform operates across case intake, adverse event monitoring, literature surveillance, signal detection, aggregate reporting, and risk management, leveraging contextual reasoning and domain-trained models to support regulatory-grade decision-making. It also includes human-in-the-loop controls to ensure compliance with FDA and global pharmacovigilance standards while significantly reducing manual effort in case processing by up to 80%, improving reviewer productivity by up to 75%, and enabling up to 50% touchless workflows by minimizing repetitive tasks and enhancing prioritization of safety signals in large-scale pharmaceutical datasets.
Artificial Intelligence (AI)-Driven Drug Safety And Pharmacovigilance Platforms Market Company Landscape And Strategic Competition
Major companies operating in the artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms market are Microsoft Corporation; International Business Machines Corporation; Accenture plc; Oracle Corporation; Cognizant Technology Solutions Corporation; IQVIA Holdings Inc.; Wipro Limited; ICON Public Limited Company; Fortrea; Clarivate Plc; Genpact Limited; Veeva Systems Inc.; ArisGlobal; Certara Inc.; Tempus AI Inc.; Komodo Health Inc.; Elsevier B.V.; Navitas Life Sciences; PrimeVigilance; Ennov Group SAS; Cloudbyz Inc.; Phesi; Medrio Inc.; Genomics England Limited
Access The Complete Artificial Intelligence (AI)-Driven Drug Safety And Pharmacovigilance Platforms Market Report:
Artificial Intelligence (AI)-Driven Drug Safety And Pharmacovigilance Platforms Market Geographic Distribution And Regional Opportunities
North America was the largest region in the artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.